Oppenheimer Asset Management Inc. acquired a new position in shares of Shire PLC (NASDAQ:SHPG) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 3,286 shares of the biopharmaceutical company’s stock, valued at approximately $596,000.
Several other hedge funds have also recently modified their holdings of SHPG. Morgan Stanley boosted its stake in shares of Shire by 25.7% during the second quarter. Morgan Stanley now owns 426,212 shares of the biopharmaceutical company’s stock worth $71,946,000 after buying an additional 87,126 shares during the period. Omni Partners LLP acquired a new stake in shares of Shire during the second quarter worth about $8,297,000. Canyon Capital Advisors LLC acquired a new stake in shares of Shire during the second quarter worth about $14,686,000. Rehmann Capital Advisory Group boosted its stake in shares of Shire by 226.9% during the second quarter. Rehmann Capital Advisory Group now owns 680 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 472 shares during the period. Finally, GAM Holding AG boosted its stake in shares of Shire by 2,242.5% during the second quarter. GAM Holding AG now owns 46,850 shares of the biopharmaceutical company’s stock worth $7,908,000 after buying an additional 44,850 shares during the period. 17.89% of the stock is currently owned by institutional investors.
Shares of NASDAQ:SHPG opened at $179.15 on Wednesday. The company has a debt-to-equity ratio of 0.36, a current ratio of 0.92 and a quick ratio of 0.51. The stock has a market capitalization of $53.58 billion, a P/E ratio of 11.83, a PEG ratio of 1.57 and a beta of 1.02. Shire PLC has a 52 week low of $123.73 and a 52 week high of $182.36.
Shire (NASDAQ:SHPG) last announced its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported $3.64 EPS for the quarter, missing the Zacks’ consensus estimate of $3.65 by ($0.01). Shire had a net margin of 30.63% and a return on equity of 12.70%. The firm had revenue of $3.87 billion during the quarter. During the same period in the prior year, the firm posted $3.81 EPS. The firm’s revenue for the quarter was up 4.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Shire PLC will post 15.13 earnings per share for the current fiscal year.
Several equities research analysts have recently weighed in on the stock. Cantor Fitzgerald set a $222.00 target price on shares of Shire and gave the stock a “buy” rating in a research note on Tuesday, July 31st. Royal Bank of Canada set a $188.00 price objective on shares of Shire and gave the company a “buy” rating in a research report on Thursday, July 19th. Sanford C. Bernstein downgraded shares of Shire from an “outperform” rating to a “market perform” rating in a research report on Tuesday, September 4th. ValuEngine upgraded shares of Shire from a “sell” rating to a “hold” rating in a research report on Friday, September 21st. Finally, BidaskClub downgraded shares of Shire from a “hold” rating to a “sell” rating in a research report on Thursday, August 16th. Eight analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $201.11.
COPYRIGHT VIOLATION NOTICE: “Oppenheimer Asset Management Inc. Acquires Shares of 3,286 Shire PLC (SHPG)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/11/07/oppenheimer-asset-management-inc-acquires-shares-of-3286-shire-plc-shpg.html.
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Further Reading: Return on Investment (ROI)
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.